Drug
Aln Ttrsc04
Aln Ttrsc04: highest development phase Phase 1, developed by Alnylam Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALN-TTRSC04 NCT05661916 | Phase 1 | Transthyretin-Mediated Amyloidosis |
Latest
No recent events.
Follow Aln Ttrsc04 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.